Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 270

1.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

PMID:
25991002
2.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB.

Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18.

PMID:
25788491
3.

Expertise vs evidence in assessment of breast biopsies: an atypical science.

Davidson NE, Rimm DL.

JAMA. 2015 Mar 17;313(11):1109-10. doi: 10.1001/jama.2015.1945. No abstract available.

PMID:
25781438
4.

Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai ZA.

Cancer Cell. 2015 Mar 9;27(3):354-69. doi: 10.1016/j.ccell.2015.02.006.

PMID:
25759021
5.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

PMID:
25733599
6.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju435. doi: 10.1093/jnci/dju435. Print 2015 Mar.

PMID:
25650315
7.

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.

Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T.

Hum Mol Genet. 2015 Apr 15;24(8):2318-29. doi: 10.1093/hmg/ddu749. Epub 2015 Jan 9.

PMID:
25576899
8.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL.

Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.

PMID:
25527356
9.

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL.

Lab Invest. 2015 Apr;95(4):385-96. doi: 10.1038/labinvest.2014.157. Epub 2014 Dec 15. Review.

PMID:
25502176
10.

Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T.

J Clin Endocrinol Metab. 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282. Epub 2014 Dec 9.

PMID:
25490274
11.

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer.

Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL.

Br J Cancer. 2015 Jan 6;112(1):61-8. doi: 10.1038/bjc.2014.573. Epub 2014 Dec 4.

PMID:
25474246
12.

Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM.

Lab Invest. 2015 Mar;95(3):334-41. doi: 10.1038/labinvest.2014.139. Epub 2014 Nov 24.

PMID:
25418580
13.

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM.

Clin Cancer Res. 2015 May 1;21(9):2138-47. doi: 10.1158/1078-0432.CCR-14-0861. Epub 2014 Oct 14.

PMID:
25316811
14.

Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.

Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V.

Clin Cancer Res. 2014 Dec 1;20(23):5995-6005. doi: 10.1158/1078-0432.CCR-14-1622. Epub 2014 Sep 25.

PMID:
25255793
15.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S.

Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.

PMID:
25214542
16.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

PMID:
25117817
17.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

18.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P.

Br J Cancer. 2014 Sep 9;111(6):1201-12. doi: 10.1038/bjc.2014.396. Epub 2014 Jul 17.

19.

ERβ splice variant expression in four large cohorts of human breast cancer patient tumors.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL.

Breast Cancer Res Treat. 2014 Aug;146(3):657-67. doi: 10.1007/s10549-014-3050-3. Epub 2014 Jul 10.

PMID:
25007965
20.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk